TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05751499

Intervention type: DIAGNOSTIC_TEST
Intervention: • Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN
Description: * Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: • Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN
Description: * Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale
Study: NCT05414786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer mRNA Vaccine (100µg)
Description: * 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study
Study: NCT04792554

Intervention type: OTHER
Intervention: Neurocognitive tests and blood taking
Description: Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
Study: NCT06427486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parents Telecoaching Intervention
Description: - Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
Study: NCT06353282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
Study: NCT04695990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wenyang Huoxue Decoction
Description: Wenyang Huoxue granules
Study: NCT05136092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cohort 1: HFCS (fructose) fed
Description: Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cohort 2: D-Xylose (xylose-fed)
Description: Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml
Study: NCT06297135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
Study: NCT06070688

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV® biomarker test
Description: one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
Study: NCT05761834

Intervention type: OTHER
Intervention: Sample blood and 2D-echocardiography with Doppler
Description: Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.

Intervention type: OTHER
Intervention: Sample blood and 2D-echocardiography with Doppler
Description: Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
Study: NCT05250895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT04429230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial pulsed current stimulation (tPCS)
Description: Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial pulsed current stimulation (tPCS)
Description: Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study: NCT06373744

Intervention type: DRUG
Intervention: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Description: The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Study: NCT06449300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise-LVT
Description: (low volume training - 3 sessions of 12 exercises per week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise-MVT
Description: (moderate volume training - 4 sessions of 12 exercises per week)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise-HVT
Description: (high volume training - 5 sessions of 12 exercises per week)
Study: NCT06259058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2400 mg/m² continuous IV infusion in 46 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2400 mg/m² continuous IV infusion in 46 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m² on Day 1 of a 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m² on Day 1 of a 14-day cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 30Gy/5Fx
Study: NCT05787912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid after photobiomodulation
Description: The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
Study: NCT04695990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wenyang Huoxue placebo
Description: Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
Study: NCT06179550

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study: NCT05817630

Intervention type: OTHER
Intervention: Silicone oil Tamponade for Retinal Detachment
Description: eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
Study: NCT04647383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study: NCT05376618

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05143203

Intervention type: OTHER
Intervention: Self-hypnosis training
Description: Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires

Intervention type: OTHER
Intervention: Self-hypnosis training
Description: Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
Study: NCT05501249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Integrated Cognitive Motor Training
Description: Aquatic exercise class with focus on cognitive and physical exercise
Study: NCT05197829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
Study: NCT05021913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKL crosslinked sodium hyaluronate 23
Description: is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Volift™ with lidocaine (Allergan, Inc)
Description: is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
Study: NCT04882137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education plus Coaching
Description: Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
Study: NCT06004622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calgary Family Intervention Model
Description: under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
Study: NCT05333926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHNA-001
Description: 3-month digital therapy program designed to reduce the severity of IBS symptoms
Study: NCT06555380

Intervention type: BEHAVIORAL
Intervention: The one-year intervention
Description: A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.

Intervention type: BEHAVIORAL
Intervention: The three-year intervention
Description: A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
Study: NCT05888584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research readiness tool
Description: Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
Study: NCT04258358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASCADE ways of working
Description: Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
Study: NCT05622786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGT - physical rehab
Description: High Intensity Gait Training using treadmill and overhead harness for fall prevention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity physical therapy
Description: Low Intensity Gait Activities
Study: NCT05434611

Intervention type: DIAGNOSTIC_TEST
Intervention: S100A12
Description: The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease

Intervention type: DIAGNOSTIC_TEST
Intervention: S100A12
Description: The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
Study: NCT05076435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic crystalloids
Description: Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloids
Description: Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy.
Study: NCT05239299

Intervention type: OTHER
Intervention: No intervention, observational study
Description: Focus Group

Intervention type: OTHER
Intervention: No intervention, observational study
Description: Focus Group
Study: NCT05159674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine+electroacupuncture compound anesthesia
Description: Dexmedetomidine and acupuncture were given together to induce anesthesia
Study: NCT04925713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFx-Hu2.0
Description: The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses.
Study: NCT06306092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep on Schedule
Description: Sleep education at school

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology restriction
Description: Reduction of electronic media use before bedtime
Study: NCT06043206

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Bariatric Surgery

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Bariatric Surgery